You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

68 search results for: guidelines

expert video

IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP

42 min

Rhinology

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.

expert video

Expert Discussion: Partnering With Patients to Improve CRSwNP Outcomes

15 min

Rhinology

Prof. Hellings discusses the importance of partnering with patients and considering the clinical importance of symptom improvements.

expert video

Clinical Management of CRSwNP: Maximizing Symptom Improvement

17 min

Rhinology

Prof. Fokkens presents recent evidence of biologic effectiveness for CRSwNP from the real-world setting

expert video

The Prevalence and Burden of Type 2 Inflammation in Patients With CRSwNP

8 min

Rhinology

Dr. Stella Lee educates on the immune responses mediating CRSwNP and the prevalence of type 2 inflammation.

expert video

Clinical Remission as a Goal in Asthma Clinical Practice

2 min

Pulmonology

Profs. Alberto Papi and Ian Pavord discuss clinical remission as a goal in asthma clinical practice beyond symptom control

interactivity

Adult Asthma Interactive Patient Cases

15 min

Pulmonology

Explore 3 hypothetical patient cases using guideline-based checklists for assessment and diagnosis of type 2 inflammation in adult asthma

expert video

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

3 min

Rhinology

Prof. Peter Hellings highlights the EPOS/EUFOREA 2024 definition of remission and calls for an elevation of treatment goals in CRSwNP.

interactivity

Pediatric Asthma Patient Case Tool: Ash

5 min

Pulmonology

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients

expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

5 min

Rhinology

Prof. Peter Hellings explores the concept of disease control in CRSwNP.

interactivity

Partnering With Patients: Scores That Matter in CRSwNP

5 min

Rhinology

Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life

interactivity

Eosinophilic Esophagitis (EoE) Pediatric Interactive Patient Case

8 min

Gastroenterology

Experience a pediatric patient's journey from infancy to adolescence with guideline-based learnings on EoE diagnosis, treatment, and long-term care.

expert video

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

8 min

Rhinology

Prof. Eugenio De Corso describes the importance of real-world evidence for understanding the prospects of remission and the emerging evidence of biologic effectiveness for patients with CRSwNP.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ChinaChange country/region